Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMED3 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
TMED3 siRNA is a small interfering RNA designed to silence the expression of the Transmembrane p24 trafficking protein 3 (TMED3) gene. TMED3 is a member of the p24 family involved in protein trafficking between the endoplasmic reticulum and the Golgi apparatus. In the context of oncology, particularly breast cancer, TMED3 is often overexpressed and associated with poor prognosis, tumor progression, and immune suppression. By utilizing RNA interference (RNAi), TMED3 siRNA reduces TMED3 mRNA levels, leading to decreased protein expression. Research indicates that knockdown of TMED3 inhibits the migratory and invasive capacities of cancer cells and may modulate the tumor immune microenvironment by influencing the infiltration of immune cells and the expression of immune checkpoint genes.
- Other names
- siRNA-TMED3siRNA-TMED-3siRNA-TMED 3TMED3-siRNATMED-3-siRNATMED 3-siRNA
Beyond the preview
Go deeper on TMED3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMED3 siRNA.